Figure 4.
Effect of CD33 expression levels on (A) relapse, (B) overall survival and (C) early mortality (60 days) in patients randomised to receive 6mg/m2 or 3mg/m2 GO dose
Forest plot analysis of 464 younger patients (NCRI-AML17 trial) assessable for GO vs no GO comparison. Patients were stratified into CD33 expression quartile using CD33-MFI and %CD33-positivity.